Promoter holding
64.27%
ML
Mepromax Life Sciences Private Limited - Due diligence report
A 360° intelligence report on Mepromax Life Sciences Private Limited: trust score, financial health, credit view, compliance, directors, gro…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Mepromax Life Sciences Private Limited — 360° Intelligence Report
Generated from MCA filings & public records93/100
Trust Score
Low Risk
Mepromax Life Sciences Private Limited is assessed as Low Risk with a Trust Score of 93/100. Mepromax Life Sciences Private Limited is an active private limited indian non-government company incorporated in 2005, operating in the Pharma sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 21 Jul 2026 from the latest processed filings. Mepromax Life Sciences Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
93/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
92/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 1 open (6.37 cr) · 2 satisfied (12.30 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Icici Bank Limited | 2 | 48.0 cr |
| Others | 1 | 48.0 cr |
Compliance Score: 92/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Delayed payments to MSME suppliers disclosed (12 disclosure(s)).
- 2 active GST registration(s).
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| PRAKASH NAVINCHANDRA SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| BHARATKUMAR CHABILDAS SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SURESH CHHABILDAS SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJESH SUMANLAL SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 4 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-
Promoters hold the largest single block of equity - exact percentages are part of the full report.
Key managerial personnel: PRAKASH NAVINCHANDRA SHAH (Whole-time director) · BHARATKUMAR CHABILDAS SHAH (Whole-time director) · SURESH CHHABILDAS SHAH (Whole-time director) · RAJESH SUMANLAL SHAH (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 65 · Distress 90
Growth signals & trust indicators
Profit expanded 1.42 year-on-year.
Net margin improved to 2.1x.
Operating for 21+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 26.55 Lakh.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence92/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment75/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 6.37 cr already registered.
- Compliance record supports lending.
Investor view81/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
20 Jan 2015
Director ceased
PRAKASH NAVINCHANDRA SHAH
Director ceased
BHARATKUMAR CHABILDAS SHAH
Director ceased
SURESH CHHABILDAS SHAH
Director ceased
RAJESH SUMANLAL SHAH
15 Jul 2014
Director ceased
CHIRAG JAMANBHAI DADHANIA
01 Mar 2013
Director ceased
ANILKUMAR RASIKLAL PATEL
21 Jun 2012
Charge satisfied
Icici Bank Limited
17 Sep 2007
Director ceased
UTTAMKUMAR RASIKLAL JAVIA
14 Sep 2007
Charge created
Others - 6.37 cr
19 Jan 2007
Charge created
Icici Bank Limited - 6.15 cr
31 Jul 2006
Charge created
Icici Bank Limited - 6.15 cr
15 Jun 2006
Director appointed
PRAKASH NAVINCHANDRA SHAH (Whole-time director)
Director appointed
BHARATKUMAR CHABILDAS SHAH (Whole-time director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold the largest single block of equity as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Lark Laboratories | U24230DL1979PLC009548 | New Delhi, Delhi, India |
| Brichem Sciences | U24304GJ2016PTC094569 | Ahmedabad, Gujarat, India |
| Bueno Salud Care | U24304GJ2016PTC094652 | Ahmedabad, Gujarat, India |
| Saimirra | U24232TN2000PTC044315 | Chennai, Tamil Nadu, India |
| Brooks Laboratories | L24232HP2002PLC000267 | Nalagarh, Himachal Pradesh, India |
| Vasudha Specialities Private Limited | U24110MH1986PTC039676 | Panvel, Maharashtra, India |
| Fortune Biotech | U24230TG1993PLC016149 | Tirumalagiri, Telangana, India |
| Enicar Pharmaceuticals Private Limited | U24230MH1994PTC079450 | Boisar, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Mepromax Life Sciences Private Limited before audits and certifications: compliance score 92/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Mepromax Life Sciences Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 65/100, margin trends, ownership structure and peer set for Mepromax Life Sciences Private Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 93/100, distress signals and MSME payment-delay disclosures - know whether Mepromax Life Sciences Private Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Mepromax Life Sciences Private Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Mepromax Life Sciences Private Limited an active company?
Mepromax Life Sciences Private Limited has MCA status “Active” with a compliance score of 92/100 (Low Risk).
Is Mepromax Life Sciences Private Limited financially healthy?
Mepromax Life Sciences Private Limited has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Mepromax Life Sciences Private Limited?
Its overall Trust Score is 93/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Mepromax Life Sciences Private Limited?
Promoters hold the largest single block of equity - exact percentages are in the full report. 4 active director(s) are on record.
Does Mepromax Life Sciences Private Limited have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.
Is Mepromax Life Sciences Private Limited up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 92/100 (Low Risk).
Is it risky to lend to Mepromax Life Sciences Private Limited?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
